Back to Results

Aytu BioScience Inc (AYTU)

Aytu BioPharma, Inc. is a pharmaceutical company listed on the NASDAQ under the ticker AYTU. The company focuses on commercializing prescription therapeutics in the United States and abroad. Its product portfolio includes treatments for attention deficit hyperactivity disorder, such as Adzenys XR-ODT, Cotempla XR-ODT, and Metadate CD, as well as pediatric products including Karbinal ER for allergic conditions and the fluoride-based vitamin products Poly-Vi-Flor and Tri-Vi-Flor. Founded as Aytu BioScience, Inc., the company adopted the Aytu BioPharma name in March 2021 and is headquartered in Denver, Colorado.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-AYTU
$2.32
7.0% Upside
Fair
$9.50
337.8% Upside
Bargain
Fair
—
—
—
0.0%
September 29, 2026
-0.7x
0.7x
0.4x
23.184 M
19.514 M
49.7%
71.1%
-6.2
—
-4.8%
Valuation • Fair Value

Aytu BioScience Inc (NASDAQ-AYTU) Fair Value by Valuation Model

Compare the primary fair value estimate for Aytu BioScience Inc (NASDAQ-AYTU) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$2.32

Estimated upside of 7.0% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$2.32

Comparable-company valuation reference.

Analyst Price Target

$9.50

Analysts imply upside of 337.8%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Aytu BioScience Inc (NASDAQ-AYTU) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Aytu BioScience Inc (NASDAQ-AYTU)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

56.599 M

Current operating scale indicator.

Revenue Forecast

53.4 M

Forward revenue estimate.

EBITDA

-2.625 M

Current operating profitability reference.

EBITDA Forecast

-7.9 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Aytu BioScience Inc (NASDAQ-AYTU) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Aytu BioScience Inc (NASDAQ-AYTU)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-4.28

No elevated caution signal from this screen.

Altman Z-Score

-6.2

Lower score that deserves closer risk review.

FCF / Net Income

-4.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Aytu BioScience Inc (NASDAQ-AYTU). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Aytu BioScience Inc (NASDAQ-AYTU)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 29, 2026

Days to Earnings

70

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Aytu BioScience Inc (NASDAQ-AYTU), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Aytu BioScience Inc (NASDAQ-AYTU) Stock Forecast & Technical Outlook

Review Aytu BioScience Inc (NASDAQ-AYTU) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Aytu BioScience Inc (NASDAQ-AYTU) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Aytu BioScience Inc (NASDAQ-AYTU) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Aytu BioScience Inc (NASDAQ-AYTU) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Aytu BioScience Inc (NASDAQ-AYTU) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Aytu BioScience Inc (NASDAQ-AYTU) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Aytu BioScience Inc (NASDAQ-AYTU)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Aytu BioScience Inc (NASDAQ-AYTU) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

Aytu BioScience Inc (NASDAQ-AYTU) Stock FAQ

Quick answers about Aytu BioScience Inc (NASDAQ-AYTU) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$2.32
Estimated upside 7.0%
Valuation Rating
Undervalued
Estimated upside of 7.0%
Analyst Target
$9.50
Implied upside 337.8%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Aytu BioScience Inc (NASDAQ-AYTU) is $2.32. This implies an estimated upside of 7.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 7.0% versus the current market price.

The available analyst price target for Aytu BioScience Inc (NASDAQ-AYTU) is $9.50. The analyst target implies estimated upside of 337.8%.

The current financial health read for Aytu BioScience Inc (NASDAQ-AYTU) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Aytu BioScience Inc (NASDAQ-AYTU) is September 29, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Aytu BioScience Inc (NASDAQ-AYTU) is -0.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Aytu BioScience Inc is 23.184 M.

The current enterprise value listed for Aytu BioScience Inc is 19.514 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Aytu BioScience Inc is NASDAQ-AYTU, and the stock is listed on NASDAQ.

Aytu BioScience Inc (NASDAQ-AYTU) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Aytu BioScience Inc is 49.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Aytu BioScience Inc is 71.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NASDAQ View more

AstraZeneca PLC ADR (AZN) AstraZeneca PLC ADR (AZN)
Sanofi ADR (SNY) Sanofi ADR (SNY)
Royalty Pharma Plc (RPRX) Royalty Pharma Plc (RPRX)
Viatris Inc (VTRS) Viatris Inc (VTRS)
Jazz Pharmaceuticals PLC (JAZZ) Jazz Pharmaceuticals PLC (JAZZ)
Axsome Therapeutics Inc (AXSM) Axsome Therapeutics Inc (AXSM)
Corcept Therapeutics Incorporated (CORT) Corcept Therapeutics Incorporated (CORT)
Crinetics Pharmaceuticals Inc (CRNX) Crinetics Pharmaceuticals Inc (CRNX)
Liquidia Technologies Inc (LQDA) Liquidia Technologies Inc (LQDA)
Belite Bio Inc ADR (BLTE) Belite Bio Inc ADR (BLTE)
Ligand Pharmaceuticals Incorporated (LGND) Ligand Pharmaceuticals Incorporated (LGND)
Definium Therapeutics Inc (DFTX) Definium Therapeutics Inc (DFTX)
Amneal Pharmaceuticals Inc Class A (AMRX) Amneal Pharmaceuticals Inc Class A (AMRX)
Indivior PLC (INDV) Indivior PLC (INDV)
Edgewise Therapeutics Inc (EWTX) Edgewise Therapeutics Inc (EWTX)
Enliven Therapeutics Inc (ELVN) Enliven Therapeutics Inc (ELVN)
Alumis Inc (ALMS) Alumis Inc (ALMS)
Structure Therapeutics Inc ADR (GPCR) Structure Therapeutics Inc ADR (GPCR)
MBX Biosciences Inc (MBX) MBX Biosciences Inc (MBX)
Supernus Pharmaceuticals Inc (SUPN) Supernus Pharmaceuticals Inc (SUPN)
ATAI Beckley Inc (ATAI) ATAI Beckley Inc (ATAI)
Regencell Bioscience Holdings Ltd (RGC) Regencell Bioscience Holdings Ltd (RGC)
Tarsus Pharmaceuticals Inc (TARS) Tarsus Pharmaceuticals Inc (TARS)
Trevi Therapeutics Inc (TRVI) Trevi Therapeutics Inc (TRVI)